<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>alveolar histology &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/alveolar-histology/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 17 Oct 2026 10:49:11 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>alveolar histology &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>TRK Protein Staining in Childhood Rhabdomyosarcoma Flags Aggressive Tumors but Misses the Gene Fusions That Matter</title>
		<link>https://bioengineer.org/trk-protein-staining-in-childhood-rhabdomyosarcoma-flags-aggressive-tumors-but-misses-the-gene-fusions-that-matter/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Sat, 17 Oct 2026 10:49:11 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[alveolar histology]]></category>
		<category><![CDATA[biomarker screening]]></category>
		<category><![CDATA[fluorescence in situ hybridization]]></category>
		<category><![CDATA[Immunohistochemistry]]></category>
		<category><![CDATA[next-generation sequencing]]></category>
		<category><![CDATA[NTRK fusions]]></category>
		<category><![CDATA[Pediatric Oncology]]></category>
		<category><![CDATA[rhabdomyosarcoma]]></category>
		<category><![CDATA[Semmelweis University]]></category>
		<category><![CDATA[targeted therapy]]></category>
		<category><![CDATA[TRK inhibitors]]></category>
		<category><![CDATA[tumor recurrence]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=425907</guid>

					<description><![CDATA[A Hungarian study of 45 pediatric rhabdomyosarcoma cases found TRK protein expression in 38 percent of tumors—concentrated in the aggressive alveolar subtype—but molecular testing uncovered no NTRK fusions, exposing the limits of immunohistochemistry as a screening tool while hinting at a new prognostic role for staining patterns.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">425907</post-id>	</item>
	</channel>
</rss>
